Structure Therapeutics (GPCR) Cash from Financing Activities (2022 - 2026)

Structure Therapeutics' Cash from Financing Activities history runs 5 years deep, the most recent figure standing at -$1.7 million for Q1 2026.

• On a quarterly basis, Cash from Financing Activities fell 315.33% year-over-year to -$1.7 million in Q1 2026; TTM through Mar 2026 was $760.0 million, a 47.46% increase from a year earlier, with the FY2025 full-year figure at $762.5 million, up 47.99% from the prior year.
• Cash from Financing Activities declined to -$1.7 million in Q1 2026 per GPCR's latest filing, from $705.0 million in the prior quarter.
• Across five years, Cash from Financing Activities topped out at $705.0 million in Q4 2025 and bottomed at -$1.7 million in Q1 2026.
• The 5-year median for Cash from Financing Activities is $615000.0 (2024), against an average of $103.3 million.
• Across the five-year window, Cash from Financing Activities soared 173400.67% in 2024 and tumbled 315.33% in 2026, its largest moves.
• Year by year, Cash from Financing Activities stood at -$316000.0 in 2022, then surged by 89223.1% to $281.6 million in 2023, then plunged by 99.78% to $615000.0 in 2024, then surged by 114532.03% to $705.0 million in 2025, then plunged by 100.25% to -$1.7 million in 2026.
• Per Business Quant, the three latest GPCR Cash from Financing Activities figures stand at -$1.7 million (Q1 2026), $705.0 million (Q4 2025), and $56.2 million (Q3 2025).